{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:45:52Z","timestamp":1787010352004,"version":"build-2736575974"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Four cases of thyroid cancer became radioiodine-refractory following conventional treatments. While no RAI-avid lesion was noticed in the initial whole-body radioiodine scan (WBIS), their metastatic foci had trace avidity. They were diagnosed as TENNIS; 2 cycles of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA-TATE were administrated, then the thyroglobulin levels dropped significantly. The PRRT was discontinued, and the diagnostic WBIS was repeated. Surprisingly, the scan revealed increased considerable tracer uptake in the metastatic foci. This restoration of radioiodine uptake seems to occur due to PRRT-induced tumor irradiation. Suggesting PRRT may serve as a potential re-differentiation strategy in TENNIS.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005809","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T01:00:10Z","timestamp":1749171610000},"page":"e477-e479","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Revolutionizing Thyroid Cancer Treatment: Restoring Radioiodine Avidity After PRRT\u2014A Case Series"],"prefix":"10.1097","volume":"50","author":[{"given":"Atena","family":"Aghaee","sequence":"first","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Soltani","sequence":"additional","affiliation":[{"name":"Kidney Transplantation Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Soltani","sequence":"additional","affiliation":[{"name":"Oncosurgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Sahafi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Sadeghpour","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"R1-20250630","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.3390\/cancers15174290","article-title":"Molecular theranostics in radioiodine-refractory differentiated thyroid cancer","volume":"15","author":"Petranovi\u0107 Ov\u010dari\u010dek","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R2-20250630","first-page":"269","article-title":"Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: a case report of significant response to lu177 DOTA-TATE treatment","volume":"66","author":"Ataei-Nakhaei","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"R3-20250630","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12885-021-08257-x","article-title":"Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review","volume":"21","author":"Maghsoomi","year":"2021","journal-title":"BMC Cancer"},{"key":"R4-20250630","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00005-014-0318-6","article-title":"Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity","volume":"63","author":"Czepczy\u0144ski","year":"2015","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"R5-20250630","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/thy.2013.0225","article-title":"Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients","volume":"24","author":"Versari","year":"2014","journal-title":"Thyroid"},{"key":"R6-20250630","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/RLU.0000000000003110","article-title":"Peptide receptor radionuclide therapy in patients with differentiated thyroid cancer: a meta-analysis","volume":"45","author":"Lee","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R7-20250630","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/1450-1147.89779","article-title":"Improved quality of life in patients treated with Peptide radionuclides","volume":"10","author":"Traub-Weidinger","year":"2011","journal-title":"World J Nucl Med"},{"key":"R8-20250630","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1097\/RLU.0000000000002219","article-title":"177Lu-DOTATATE therapy in radioiodine-refractory differentiated thyroid cancer: a single center experience","volume":"43","author":"Roll","year":"2018","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T12:01:23Z","timestamp":1751284883000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005809","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"2024-09-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}